Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis

Drug Metabolism and Disposition

Volumn 39, Issue 4, 2011, Pages 571-579

  Li, Peng ^a,b   Robertson, Thomas A ^a,b   Thorling, Camilla A ^a,b   Zhang, Qian ^a,b   Fletcher, Linda M ^a   Crawford, Darrell H G ^a   Roberts, Michael S ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CYTOCHROME P450; CYTOCHROME P450 2D2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A2; GLUCURONOSYLTRANSFERASE; LABETALOL; METOPROLOL; PHENAZONE; PROPRANOLOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPARENT DISTRIBUTION RATIO; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; GENE EXPRESSION; HISTOPATHOLOGY; INTRINSIC ELIMINATION CLEARANCE; LIPID DIET; LIPOPHILICITY; LIVER EXTRACTION; LIVER FIBROSIS; LIVER MICROSOME; MALE; MEAN TRANSIT TIME; MEMBRANE PERMEABILITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PERMEABILITY SURFACE AREA PRODUCT; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; CATIONS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; EMULSIONS; FATS; FATTY LIVER; LIVER; LIVER CIRRHOSIS; MALE; RATS; RATS, WISTAR;

RATTUS;

EID: 79952851326     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036806     Document Type: Article

References (40)

1. Cheung K, Hickman PE, Potter JM, Walker NI, Jericho M, Haslam R, and Roberts MS (1996) An optimized model for rat liver perfusion studies. J Surg Res 66:81-89. (Pubitemid 27009380)
2. Chtioui H, Semela D, Ledermann M, Zimmermann A, and Dufour JF (2007) Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int 27:764-771. (Pubitemid 47062043)
3. Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, and Cherrington NJ (2008) Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 82:959-964.
4. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, and Cherrington NJ (2009) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
5. Folch J, Lees M, and Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
6. Hung DY, Chang P, Cheung K, McWhinney B, Masci PP, Weiss M, and Roberts MS (2002a) Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther 301:1079-1087. (Pubitemid 34595100)
7. Hung DY, Chang P, Cheung K, Winterford C, and Roberts MS (2002b) Quantitative evaluation of altered hepatic spaces and membrane transport in fibrotic rat liver. Hepatology 36:1180-1189. (Pubitemid 35253434)
8. Hung DY, Chang P, Weiss M, and Roberts MS (2001) Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. J Pharmacol Exp Ther 297:780-789. (Pubitemid 32378012)
9. Hung DY, Siebert GA, Chang P, Burczynski FJ, and Roberts MS (2005) Reduced hepatic extraction of palmitate in steatosis correlated to lower level of liver fatty acid binding protein. Am J Physiol Gastrointest Liver Physiol 288:G93-G100. (Pubitemid 39665224)
10. Hung DY, Siebert GA, Chang P, Whitehouse MW, Fletcher L, Crawford DH, and Roberts MS (2006) Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation. Am J Physiol Gastrointest Liver Physiol 290:G343-G351.
11. Ishak KG, Zimmerman HJ, and Ray MB (1991) Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res 15:45-66.
12. Koteish A and Mae Diehl A (2002) Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16:679-690.
13. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, and McLean AJ (2005) The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 44:187-200. (Pubitemid 40188940)
14. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35:1970-1978. (Pubitemid 47481594)
15. Makino T, Shimizu R, Kanemaru M, Suzuki Y, Moriwaki M, and Mizukami H (2009) Enzymatically modified isoquercitrin, alpha-oligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral administration in rats. Biol Pharm Bull 32:2034-2040.
16. Marsman H, Matsushita T, Dierkhising R, Kremers W, Rosen C, Burgart L, and Nyberg SL (2004) Assessment of donor liver steatosis: pathologist or automated software? Hum Pathol 35:430-435. (Pubitemid 38507079)
17. Matsubara T, Koike M, Touchi A, Tochino Y, and Sugeno K (1976) Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal Biochem 75:596-603.
18. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, and McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419. (Pubitemid 29258890)
19. Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, and PasanenM(2000) Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 33:893-901.
20. O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, and Nunes DP (2000) An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 114:712-718. (Pubitemid 33051906)
21. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653. (Pubitemid 8253670)
22. Prompila N, Wittayalertpanya S, and Komolmit P (2008) Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease. J Med Assoc Thai 91:733-738. (Pubitemid 351776227)
23. Roberts MS and Anissimov YG (1999) Modeling of hepatic elimination and organ distribution kinetics with the extended convection-dispersion model. J Pharmacokinet Biopharm 27:343-382. (Pubitemid 30228020)
24. Roberts MS, Donaldson JD, and Rowland M (1988) Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination. J Pharmacokinet Biopharm 16:41-83.
25. Roberts MS and Rowland M (1986) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm 14:227-260.
26. Sabbà C, Buonamico P, Vendemiale G, Berardi E, Antonica G, Palmieri V, Merkel C, and Palasciano G (2001) Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis. Eur J Gastroenterol Hepatol 13:163-169. (Pubitemid 32158210)
27. Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, and Hawke RL (2008) The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 36:1909-1916.
28. Sheth SG, Gordon FD, and Chopra S (1997) Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145. (Pubitemid 27058588)
29. Siebert GA, Hung DY, Chang P, and Roberts MS (2004) Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther 308:228-235. (Pubitemid 38090722)
30. Siepmann M, Nokhodian A, Thümmler D, and Kirch W (1998) Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol 54:767-771. (Pubitemid 29024212)
31. Wang MH, Palmeri ML, Guy CD, Yang L, Hedlund LW, Diehl AM, and Nightingale KR (2009) In vivo quantification of liver stiffness in a rat model of hepatic fibrosis with acoustic radiation force. Ultrasound Med Biol 35:1709-1721.
32. Weiss M (1999) Cellular pharmacokinetics: effects of cytoplasmic diffusion and binding on organ transit time distribution. J Pharmacokinet Biopharm 27:233-256.
33. Weiss M, Kuhlmann O, Hung DY, and Roberts MS (2000) Cytoplasmic binding and disposition kinetics of diclofenac in the isolated perfused rat liver. Br J Pharmacol 130:1331-1338. (Pubitemid 30488597)
34. Weiss M, Stedtler C, and Roberts MS (1997) On the validity of the dispersion model of hepatic drug elimination when intravascular transit time densities are long-tailed. Bull Math Biol 59:911-929. (Pubitemid 28378119)
35. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, and Liddle C (1998) Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27:128-133. (Pubitemid 28041545)
36. Weltman MD, Farrell GC, and Liddle C (1996) Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:1645-1653. (Pubitemid 26404230)
37. Williams RL and Mamelok RD (1980) Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 5:528-547. (Pubitemid 11170456)
38. Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, Choi PC, Chan AW, So WY, Chan FK, et al. (2008) Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 103:1682-1688.
39. Yeganeh MH and McLachlan AJ (2002) In-vitro distribution of terbinafine in rat and human blood. J Pharm Pharmacol 54:277-281. (Pubitemid 34150063)
40. Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, Zhang L, and Wang Y (2006) High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 79:1100-1107. (Pubitemid 44102717)